Company intelligence / Profile preview

Tellus There

Durham, North Carolina, United States

Ownership: Private
Development stage: Other

Overview

Tellus Therapeutics’ lead candidate, TT-20, is a small molecule therapy designed to induce regeneration of myelin-producing oligodendrocytes and repair white matter injury in preterm infants. The compound has demonstrated efficacy in animal models of perinatal brain injury. TT-20 has received Rare Pediatric Disease and Orphan Drug Designations from the FDA. IND-enabling studies are ongoing to support a Phase 1b clinical trial. No clinical results have been published yet.

Therapeutic areas: PulmonologyGastroenterologyNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Xontogeny/Xontogeny Venture Fund (“PXV Fund”)Perceptive Advisors PXV FundDuke University (technology licensing/collaboration)

Beyond the preview

Go deeper on Tellus There.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tellus There.

Explore the full profile